NovalGen announces two oral presentations at upcoming conferences

Updated pre-clinical data for NVG-444, a novel FVIII mimetic bispecific antibody with our proprietary autoregulation platform technology in patients with haemophilia A to be presented at ISTH 2023 Congress-

Updated pre-clinical data for NVG-222, a first in class half-life extended T Cell engager targeting ROR1-

London, United Kingdom, 9 June, 2023 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing disruptive therapies, based on a proprietary autoregulation (AR) platform, today announces the presentation of preclinical data on this novel technology in two separate indications at the International Society on Thrombosis and Haemostasis Congress (ISTH), 24-28 June, 2023 in Toronto and the Immuno-Oncology Summit Boston 2023, 7-9 August, 2023 in Boston. “We are delighted to be showcasing our proprietary platform, which has the potential to improve the safety profile and therapeutic index of a range of immunotherapies. Preclinical data with NVG-444 shows a reduction in thrombotic complications with a bispecific Factor VIII mimetic. These data will be presented in an oral presentation at ISTH. The AR platform is target agnostic as illustrated by its application to an extended half-life T cell engager (TCE) targeting ROR1, resulting in a dramatic reduction in toxicity, thus addressing the “Achilles heel” of TCEs allowing more patients to benefit from this off the shelf, T cell activating technology. The AR technology can be applied to a wide range of immunotherapies and heralds a new and exciting class of self-regulating drugs that respond to biological cues to avoid life-threatening toxicities,” said Professor Amit Nathwani, Founder and CEO of NovalGen. Both abstracts will be delivered as oral presentations at the conferences. Abstracts to be presented: Conference: ISTH 2023 Congress Abstract Title: Thrombin-mediated autoregulation restores sensitivity to the coagulation feedback loop and reduces the risk of prothrombotic events associated with FVIII mimetic antibodies. Abstract Presentation Number: OC 69.1 Session Title: Hemophilia – Novel therapies II Session Date: Wednesday, 28 June, 2023 Presentation Time: 10:15 am - 10:30 am Presenting Author: Vincent Muczynski Conference: Immuno-Oncology Summit Boston 2023 Abstract Title: NVG-222: A ROR1-Targeting T Cell Engager with Integral Autoregulating Capability Designed to Reduce the Risk of Serious Adverse Events Related to T Cell Activation Session Title: Bispecific Antibodies for Cancer Immunotherapy: Overcoming Obstacles to Efficacy Session Date: Tuesday, 8 August, 2023 Presentation Time: 8:05am – 8:35am Presenting Author: David Granger - Ends - Further information NovalGen Ltd. Laura Stanisci-Brown Tel.+44(0207) 139 8639 Email: l.stanisci-brown@novalgen.co.uk About NovalGen NovalGen is a privately held clinical stage immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, with the aim of creating life-saving new treatments for people with cancer. Alongside this, we are building out our autoregulation platform that can be applied to a range of therapeutic indications heralding a new era of self-regulating drugs. Our dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated products tailored to the needs of the patient. The company’s lead program, NVG-111, is an ROR1-targeting bispecific antibody T cell engager for the treatment of both hematologic malignancies and solid tumors using our breakthrough bispecific technology.